Yahoo Finance

Roth MKM last night initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $29 price target Entrada is an early-stage biopharma that seeks to solve a key bottleneck, which is effectively delivering oligo drugs into hard-to-target regions to treat diseases driven by genetic mutations, such as Duchenne muscular dystrophy and myotonic dystrophy, the analyst tells investors in a research note. The firm views the company as an “overlooked neuromuscular innovator” and says the ENTR-601-44 Phase 1 data “clean the clocks of competitors.”

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on TRDA:

• Entrada Therapeutics initiated with a Buy at Roth MKM

• Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer

• Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright

• Entrada Therapeutics’ Q3 2024 Financial Highlights

• Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)